Ind Swift Lab receives USFDA approval
Ind Swift Lab receives USFDA approval >Ind Swift Laboratories announced that the company received the USFDA approval for its API manufacturing faculty situated at Village Bhagwanpur, Derabassi, Pb. Earlier this year in February 2007, Ind Swift Laboratories (Q, N,C,F)* successfully completed USFDA inspection for Clarithromycin, active pharmaceutical ingredient (API) manufacturing facility. Incorporated in 1995, Chandigarh, India-based Ind-Swift Lab oratories (ISL) is a part of the Ind-Swift group. ISL manufactures active pharmaceutical ingredients in macrolide antibiotics, anti-allergies, cardiovascular, diabetology and anti-ulcerant segments.
Shares of the company gained Rs 0.05, or 0.09%, to settle at Rs 56.3. The total volume of shares traded was 37,295 at the BSE.(Tuesday)
